Brief: Gubra's Partner Abbvie Reports Positive Phase 1 Results For ABBV-295

Gubra A/S

09/03/2026 12:25

March 9 (Reuters) - Gubra A/S GUBRA.CO:

ABBVIE REPORTS POSITIVE PHASE 1 MULTIPLE ASCENDING DOSE RESULTS FOR ABBV-295, A LONG-ACTING AMYLIN ANALOG

ABBV-295 WAS WELL TOLERATED WITH A DOSE-DEPENDENT SIGNIFICANT AND CLINICALLY MEANINGFUL WEIGHT LOSS, COMPARED TO PLACEBO

DATA SUPPORT CONTINUED DEVELOPMENT OF ABBV-295 AS A POTENTIALLY DIFFERENTIATED TREATMENT FOR CHRONIC WEIGHT MANAGEMENT

Source text: ID:nMFN7QsZfH

Further company coverage: GUBRA.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))